Abstract: A SNP molecular marker combination for identifying an AA broiler includes 25 SNP molecular markers, SNP sites of the SNP molecular markers 1 to 25 are located at a 51st position of each of nucleotide sequences shown in SEQ ID NO: 1 to 25. The SNP molecular marker combination for identifying the AA broiler in the disclosure has apparent species specificity of the AA broiler, is a unique mutation and importance determining site for the AA broiler, and can quickly identify authenticity of the AA broiler with less genotype information, providing new technical references for the identification, conservation, and genetic breeding of chicken breeds in the future.

Abstract: The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.

Abstract: The present invention includes compositions and methods for a modified immune cell or precursor cell thereof comprising an inducible expression system. Also provided are gene edited modified immune cells suitable for T cell therapy. Methods of treatment using modified immune cells of the present invention are also provided.

Abstract: The present invention includes compositions and methods for modifying a T cell with a nucleic acid encoding a switch molecule comprising an extracellular domain comprising a membrane receptor or fragment thereof and an intracellular domain comprising a signaling receptor or fragment thereof. In one aspect, a method comprises introducing a nucleic acid encoding a switch molecule and a nucleic acid encoding a soluble fusion protein and/or a nucleic acid encoding a bispecific antibody into a population of cells comprising T cells, wherein the T cells transiently expresses the switch molecule and soluble fusion protein or bispecific antibody. In other aspect, compositions of T cells and methods of treating a disease or condition, such as cancer or an autoimmune disease, are also included.

Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.

Abstract: The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.

Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin, a HLA molecule, CTLA-4, PD1, and FAS and further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.

Abstract: Disclosed herein are anti-BCMA antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-BCMA antibodies and antigen-binding fragments (“BCMA CARs”) and genetically modified immune effector cells having such BCMA CARs. Polynucleotides encoding the anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. Compositions comprising anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. The present disclosure also relates to use of the anti-BCMA antibodies and antigen-binding fragments and genetically modified immune effector cells having such BCMA CARs in cancer treatment.

Abstract: A system and a method are provided. The system includes an airborne detection system and a ground assistance system. The airborne detection system includes an unmanned aerial vehicle, a receiving device, a transmitting device, and a connecting device. The transmitting device includes a transmitting sub-device, a transmitting coil, and a bucking coil. The receiving device includes a receiving sub-device and a three-component magnetic sensor. The connecting device includes a signal and rope composite cable and is used to connect the UAV, the transmitting device, and the receiving device. The three-component magnetic sensor is used to acquire three-component electromagnetic data. The bucking coil is disposed on an inner side of the transmitting coil, and coil winding direction of the transmitting coil and the bucking coil causes current directions flowing through the transmitting coil and the bucking coil to be opposite to each other, to reduce an electromagnetic interference.

Abstract: Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.

Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g. PD-1 or TIM-3) is downregulated.

Abstract: A stroke decision device 30 includes an acquisition section 31 configured to acquire state information including a position, a velocity, and a rotational velocity of an incoming ball, and a stroke decision section 32 configured to decide a stroke condition including a position, a velocity, and an orientation of a striking implement at a time point when hitting back the ball toward a target arrival position, based on the state information for the ball and the target arrival position when hitting back the ball with the striking implement.

Abstract: The present disclosure relates to a molecular marker of the IGF2BP1 gene related to a chicken body size trait and the use thereof, and a genetic improvement method. In the present disclosure, it is found by means of gene association analysis that a deletion mutation in a promoter region of the IGF2BP1 gene of chicken is significantly associated with the chicken body size trait.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: The present disclosure provides a series battery pack capacity on-line monitoring and charging/discharging dual-state equalization circuit and method. The series battery pack capacity on-line monitoring and charging/discharging dual-state equalization circuit includes a storage battery pack, a gating switch array, a power dissipation loop, a polarity matching switch array, an isolated DC/DC converter, a bipolar differential battery voltage measurement circuit, a micro controller unit, a charging/discharging current detection loop, and a switch circuit unit. According to the present disclosure, each series battery of the storage battery pack can be separately charged and discharged by controlling the gating switch array, the storage battery pack capacity can be detected on line, bypass discharge and parallel supplement can be carried out on the series batteries with high or low relative state of charge in two states of charging and discharging, and the power of each series battery can be efficiently equalized.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: The present application relates to an antigen-binding protein and use thereof, wherein the antigen-binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2 and an HCDR3, wherein the HCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 10, the HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 12, the HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 14; and the VL comprises an LCDR1, an LCDR2 and an LCDR3, wherein the LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 2, the LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 4, and the LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 6. The present application also relates to a pharmaceutical composition comprising the antigen-binding protein and use thereof for the treatment of a cancer.

Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g., PD-1 or TIM-3) is downregulated.